Clinical Trials Logo

Hematopoietic/Lymphoid Cancer clinical trials

View clinical trials related to Hematopoietic/Lymphoid Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05147311 Active, not recruiting - Clinical trials for Hematologic Malignancy

Positive Psychology Intervention In HSCT

PATH-3
Start date: November 17, 2021
Phase: N/A
Study type: Interventional

The main purpose of this research study is to determine if a positive psychology-based program in people who have received a stem cell transplant for blood cancer treatment is feasible and acceptable, and can help improve positive feelings, mood, quality of life, overall wellbeing and health. The Positive psychology for Allogenic Transplantation of Hematopoietic stem cell intervention (PATH), a novel 9-week phone-administered Positive psychological intervention (PPI).

NCT ID: NCT03185494 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Start date: August 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to chemotherapy.

NCT ID: NCT01056614 Active, not recruiting - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well giving fludarabine phosphate, busulfan, anti-thymocyte globulin followed by donor peripheral blood stem cell transplant, tacrolimus, and methotrexate works in treating patients with myeloid malignancies. Giving chemotherapy, such as fludarabine phosphate and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving anti-thymocyte globulin before transplant and tacrolimus and methotrexate after transplant may stop this from happening.

NCT ID: NCT00710632 Active, not recruiting - Lung Cancer Clinical Trials

Screening to Predict Weight Loss in Patients With Cancer

Start date: September 2007
Phase: N/A
Study type: Interventional

RATIONALE: Screening tests may identify people with cancer who are at high risk of losing weight and help doctors plan better treatment. PURPOSE: This clinical trial is studying how well a new screening tool works in predicting weight loss in patients with cancer.